Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

Introduction Bortezomib(Velcade®) is a proteasome inhibitorthat has shown important clinical efficacy either as a single agent or in combination with other cytostatic agents in multiple myeloma(MM). In the present protocol, bortezomibwas combined with other active substances like bendamustineand prednisone(BPV), in order to assess the efficacy and toxicity of the combination therapyin patients with relapsed or refractory MM.